Author

L. J. Alderwick

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Organism:human· 1 Organism:virus· 1

Frequent Co-Authors

J. Bacon· 3 shared A. B. Lanne· 1 shared A. Feula· 1 shared A. Fletcher· 1 shared A. Goff· 1 shared A. Yoshizawa· 1 shared C. E. M. Thornton· 1 shared C. J. McCabe· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

J. Bacon

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Mycobacterium tuberculosis modifies cell wall carbohydrates during biofilm growth with a concomitant reduction in complement activation

T. Keating, S. Lethbridge, S. R. Thomas, L. J. Alderwick, S. C. Taylor, J. Bacon

This study investigates how Mycobacterium tuberculosis modifies its cell wall carbohydrates during biofilm growth, leading to reduced complement activation via the lectin pathway.

bioRxiv · Mar 23, 2021Immunology

Azetidines kill Mycobacterium tuberculosis without detectable resistance by blocking mycolate assembly.

A. B. Lanne, Y. Cui, E. Browne, P. G. E. Craven, N. J. Cundy, N. J. Coltman, K. Dale, A. Feula, J. Frampton, A. Goff, M. A. Hama Salih, X. Lang, X. Li, C. W. Moon, M. Morton, , L. J. Alderwick

The paper identifies azetidine derivatives that kill Mycobacterium tuberculosis without resistance by inhibiting mycolate assembly, showing a novel mode of action and favorable pharmacological profiles.

bioRxiv · Sep 3, 2020 · PreprintMicrobiology

New mechanisms of radioiodide uptake revealed via a novel high throughput drug screening approach in thyroid cancer

M. L. Read, K. Brookes, C. E. M. Thornton, A. Fletcher, M. Alshahrani, R. Khan, H. R. Nieto, P. Borges de Souza, J. R. M. Webster, L. J. Alderwick, K. Boelaert, V. E. Smith, C. J. McCabe

This study identifies FDA-approved drugs that enhance radioiodide uptake through non-canonical NIS processing pathways, revealing new therapeutic strategies for thyroid cancer.

bioRxiv · Jul 21, 2020 · PreprintCancer Biology

Utilisation of the Prestwick Chemical Library (R) to identify drugs that inhibit the growth of Mycobacteria

L. J. Alderwick, P. Kanvatirth, G. Besra, R. E. Jeeves, J. Bacon

The paper screens FDA-approved drugs from the Prestwick Chemical Library against Mycobacterium species to identify antimycobacterial compounds and highlights potential drug repurposing targets.

bioRxiv · Jun 28, 2018Microbiology